Navigation Links
Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
Date:10/25/2011

al resources available to the company, is no longer tenable.

Background to Regulatory Process

In 2009, AMT filed Glybera for European marketing authorization "under exceptional circumstances". In Europe, this submission process is intended to allow drugs for extremely rare diseases to be approved, realizing that the clinical development package will never contain all the information that would be required for a more common condition.

The dossier was examined by the Committee for Advanced Therapies (CAT) and the CHMP, and in June 2011 both voted against approval of Glybera. AMT appealed the decision based on its interactions with representatives from the CHMP and two new CHMP Rapporteurs were appointed to lead the review process. During the appeal, both rapporteurs, an external scientific advisory group (SAG) consisting of European experts in the areas of gene therapy, lipid metabolism and pancreatitis, was appointed to review and analyze the data and to advise the EMA on its conclusions. The SAG concluded that Glybera should be approved under exceptional circumstances. Subsequently, the CAT performed its own analysis and also voted by a large majority in favor of Glybera marketing authorization. The advice from the SAG, the CAT and both the CHMP Rapporteurs, was provided to the CHMP. However, the CHMP did not change its previous opinion and again voted with the narrowest majority against Glybera marketing authorization. The Company has not yet been informed of the reasons for the CHMP decision.

Operations

Following a careful review of operations and resources needed for development of its remaining pipeline products, AMT management will work in close consultation with the works council to assess the impact of the review on the company's workforce. Management and board believe that for AMT to remain a viable business it needs to reduce the headcount by 50% to 45 full-time employees.

Financials

The measures announced to
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
2. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
3. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
4. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
5. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
6. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
7. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
8. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
9. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
11. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
(Date:2/27/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced ... report to their offering. , Global ... data on Trypsin globally and regionally ( Europe ... , Latin America etc.). It ... This report focuses on three primary areas; manufacture methods ...
(Date:2/27/2015)... Md. (PRWEB) February 27, 2015 ... Chromatography system (Nexera UC) can sequentially analyze up ... separation combined with high-sensitivity detection of targets by ... is designed to fulfill the measurement requirements of ... in food products, drug delivery and search for ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
... CAMBRIDGE, Mass., Oct. 31 Idenix,Pharmaceuticals, Inc., (Nasdaq: ... results for the third quarter of 2007 on Tuesday, ... In conjunction with the issuance of the press release, ... ET on Tuesday, November,6, 2007 to discuss the company,s ...
... tech development, opportunities for business growth, COLUMBUS, ... Ohio,colleges and universities increased academic research expenditures in ... than ever into high,technology R&D sectors throughout the ... high tech research, development and,commercialization, especially in the ...
... SAN FRANCISCO, Oct. 31 Medivation, Inc.,(Nasdaq: MDVN ... chief,executive officer, will present at the Acumen BioFin Rodman ... at 11:15 a.m. Eastern,Time at the New York Palace ... Medivation and its clinical,development programs for Dimebon(TM) for Alzheimer,s ...
Cached Biology Technology:Ohio Academic Institutions Increase Research and Development Investments 2Ohio Academic Institutions Increase Research and Development Investments 3Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
(Date:1/22/2015)... Fla. , Jan. 13, 2015  Today, FreeWavz ... technology, launched its crowdfunding campaign on Fundable, ... the build of production capacity to meet customer ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Haven, Conn.Paleontologists have discovered a new species of dinosaur with ... skull, according to a paper published in the April issue ... species was a plant-eating dinosaur about as big as a ... said Nicholas Longrich of Yale University, lead author of the ...
... RIVERSIDE, Calif. Robert Luck , a professor of ... California Citrus Quality Council,s prestigious Albert G. Salter Memorial Award ... Luck is a leading expert in the research ... "This is a truly deserving award for Professor Luck ...
... The Marine Protected Areas Federal Advisory Committee will meet ... Charleston, S.C. The committee advises the Department of Commerce ... to the national system of MPAs. The ... includes integrating the national MPA system with the Coastal ...
Cached Biology News:New bony-skulled dinosaur species discovered in Texas 2UC Riverside entomologist recognized for research in citrus entomology 2
The mini vertical flow workbench is designed to perform PCR protocols in a particle-free environment. The built-in UV light ensures the elimination of any nucleic acid to avoid cross-contamination....
Request Info...
... The Cellject Uno Electroporator is ... for producing optimum efficiencies in bacterial ... simply selects one of two voltages ... or four mm cuvettes. On pressing ...
Request Info...
Biology Products: